Transforming Cardiac Transplant Organ Preservation
VP.S ENCORE® is a heart transplant perfusion device designed to support longer donor heart preservation and expand what may be possible in transplant timing, access, and donor utilization.
Extending the Window for Donor Heart Viability
Cold storage forces transplant teams to work within a narrow preservation window. With roughly 4–6 hours to work with, viable donor hearts may go unused due to limited preservation time, transport constraints, donor blood requirements, and system complexity.
VP.S ENCORE® addresses these limitations using donor heart preservation technology that is designed to fit into transplant workflows while supporting longer preservation and greater transport flexibility.
VP.S ENCORE®: A Simpler Path to Donor Heart Preservation
Simple
Blood-free perfusate
Eliminates the need for donor blood, reducing compatibility constraints
Seamless integration
No specialized fluids, setup, or equipment
Portable
Intuitive compact design
Built for single-person handling and easy maneuverability
Extended battery life
Supports air travel over long distances without specialized transportation
Reliable
Double the preservation window
Preclinical studies suggest VP.S ENCORE® may extend organ viability up to eight hours
Built-in cold storage fallback
Helps protect the life-saving organ if perfusion is disrupted
Preclinical Research Signals
- Up to 24 hours of successful preservation in porcine models
- Adequate lactate levels supporting organ viability and fitness for use
- No edema observed across porcine, adult human, and pediatric hearts
“Children are an underserved population when it comes to innovation, adaptation of technology, and clinical trials. It is our duty to advocate for them and continue to advance the care in pediatric medicine.”
Joseph Turek, MD, PhD, MBA. Pediatric cardiac surgeon at Duke University
Strategic Grant Support
Breakthrough Initiative
ARPA-H/Wyss Institute
Novel Perfusate for Organ Banking
Advanced preservation solutions designed to support long-term organ banking and functional recovery.
siRNA Research Funding
Gene Delivery and Organ Genetic Modification
Research exploring therapeutic delivery during ex-vivo perfusion to enhance graft quality.
PEDS Initiative
PEDS – Pediatric Application of VP.S ENCORE®
Development of a pediatric-specific perfusion approach designed to address the unique physiological needs of small donor hearts and improve their utilization.
VP.S ENCORE® Kidney Development
VP.S ENCORE® Kidney Application
Expansion of the ENCORE® perfusion platform to support kidney preservation.
U.S. Department of Defense (DoD)
Human Forearm Perfusion and Preservation
Research focused on preserving vascularized composite tissues for potential limb reimplantation and transplantation.
FDA Breakthrough Device Designation
Shaping What Comes Next
Help us power the next phase of VP.S ENCORE® evaluation.
Connect with our team to schedule a demo, learn more about future clinical trial participation, and explore how your cardiac care center can help shape the future of donor heart preservation with VPS.